Press Release
–

Jan 4, 2022 08:00 EST

LATHAM, N.Y.,
January 4, 2022 (Newswire.com) –

Mesuron announced today that it has entered into a know-how collaboration agreement and stock purchase agreement with Mayo Clinic to further refine its protocol algorithm and analytic software for the AVALON-H90’s Ventricle Repolarization Dynamics Analysis (VRDA) output, specifically for Acute Chest Pain (ACP) patients admitted to the hospitals’ Emergency Rooms (ERs) in order to rapidly separate ACP caused by heart problems from other causes not related to the heart. As part of the agreement, Mayo Clinic became a shareholder in Mesuron Inc.

Mesuron Inc. is a U.S.-based company specializing in the development and fabrication of Superconducting Quantum Interference Device (SQUID)-based magnetometers for various applications. The use of this technology for heart screening is the company’s…